KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Accumulated Depreciation (2016 - 2018)

Arbutus Biopharma's Accumulated Depreciation history spans 9 years, with the latest figure at $6.9 million for Q4 2018.

  • On a quarterly basis, Accumulated Depreciation fell 45.58% to $6.9 million in Q4 2018 year-over-year; TTM through Dec 2018 was $6.9 million, a 45.58% decrease, with the full-year FY2018 number at $6.9 million, down 45.58% from a year prior.
  • Accumulated Depreciation hit $6.9 million in Q4 2018 for Arbutus Biopharma, up from $6.4 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation for ABUS hit a ceiling of $13.3 million in Q1 2018 and a floor of $5.9 million in Q2 2018.
  • Historically, Accumulated Depreciation has averaged $10.4 million across 5 years, with a median of $10.6 million in 2016.
  • Biggest five-year swings in Accumulated Depreciation: skyrocketed 200.65% in 2014 and later tumbled 48.92% in 2018.
  • Tracing ABUS's Accumulated Depreciation over 5 years: stood at $11.2 million in 2014, then dropped by 13.13% to $9.7 million in 2015, then grew by 10.37% to $10.7 million in 2016, then rose by 18.0% to $12.7 million in 2017, then tumbled by 45.58% to $6.9 million in 2018.
  • Business Quant data shows Accumulated Depreciation for ABUS at $6.9 million in Q4 2018, $6.4 million in Q3 2018, and $5.9 million in Q2 2018.